Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 6/20 | 0.50 |
| ▸ | FNTB | P49356 | 4/20 | 0.50 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14151236 | 1.00 | FNTA (0.50) | FNTAFNTBPGGT1BKMT2AGGPS1 | |
| SCHEMBL31310901 | 0.98 | KMT2A (0.53) | FNTAFNTBPGGT1BKMT2AGGPS1 | |
| SCHEMBL2458411 | 0.86 | FNTA (0.55) | FNTAFNTBPGGT1BKMT2AGGPS1 | |
| SCHEMBL14457808 | 0.85 | TSHR (0.41) | FNTAFNTBPGGT1B | |
| SCHEMBL2458072 | 0.85 | TSHR (0.48) | FNTAFNTBPGGT1B | |
| SCHEMBL14668879 | 0.83 | FNTA (0.46) | FNTAFNTBPGGT1BKMT2AGGPS1 | |
| SCHEMBL11481398 | 0.82 | ALDH1A1 (0.46) | FNTAFNTBPGGT1BKMT2AGGPS1 | |
| SCHEMBL14118094 | 0.82 | NR1I2 (0.56) | FNTAFNTBPGGT1BGGPS1ALDH1A1 | |
| SCHEMBL14152318 | 0.82 | NR1I2 (0.56) | FNTAFNTBPGGT1BGGPS1ALDH1A1 | |
| SCHEMBL29666437 | 0.80 | KMT2A (0.57) | FNTAFNTBPGGT1BKMT2AGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051254-B2 | Method of preparing 2,6,10-Trimethyl-1,1-dialkoxy-3,5,9-undecatriene used as an intermediate of lycopene | HANGZHOU NORMAL UNIVERSITY (CN) | 2015-06-09 | — | — | US | disclosed |
| US-20120316366-A1 | Method of Preparing 2,6,10-Trimethyl-1,1-Dialkoxy-3,5,9-Undecatriene Used as an Intermediate of Lycopene | UNIVERSITY OF SHAOXING (CN) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316366-A1 | Method of Preparing 2,6,10-Trimethyl-1,1-Dialkoxy-3,5,9-Undecatriene Used as an Intermediate of Lycopene | CDK20, PTGES, DTYMK | FNTA 40/4885FNTB 920/4885PGGT1B 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.